Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure Biosciences preps for up-list on US exchanges after Q1 earnings

Pressure Biosciences laid out its 2016 goals on Wednesday which include implementation of financial self-sufficiency and future growth and profitability as well as preparation for a targeted up-list to NASDAQ or the NYSEMKT
Pressure Biosciences preps for up-list on US exchanges after Q1 earnings
Seeks distribution partner for the Barozyme HT48 high throughput system

Pressure Biosciences Inc (OTCMKTS:PBIO) laid out its 2016 goals on Wednesday which include implementation of financial self-sufficiency and future growth and profitability as well as preparation for a targeted up-list to NASDAQ or the NYSEMKT.

The company also wants to complete the manufacture of the Barocycler 2320 EXTREME and begin the commercialisation phase for this computer-driven, new pressure-generating instrument during the second quarter, as well as secure a strategic marketing and distribution partner for the Barozyme HT48 high throughput system and for the NMR and EPR PCT-based sample preparation systems.

The near-term goals accompanied the company reporting its first quarter earnings results which saw products and services revenue increases 26% year-on-year to $510,478 and sales of Instruments and Consumables rise to $454,350 from $359,364.

Pressure BioSciences develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn life sciences sample preparation market.

The company recorded a net loss of $5.95mln in the three months to March 31, from $2mln in the same period a year ago.

"We believe the market for our pressure-based products (instruments and consumables) is large, diverse, and growing.  In order to successfully increase and expand our penetration into this market, it is essential that we continue to increase market exposure and acceptance of our novel PCT-based product line," said Richard T. Schumacher, President and CEO of PBI.

"We believe the major operational accomplishments of the 2016 first quarter – especially the co-marketing agreement with SCIEX and the development of the new Barocycler 2320EXTREME – will play key roles in increasing our visibility, acceptance, and success in penetrating this market, which will subsequently help PBI achieve rapid and dramatic growth in the near future," he added.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1504120610_biotechLatest.jpg
October 23 2017
The company is poised for a milestone-rich period over the next year or so
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use